Home » Stocks » TYME

Tyme Technologies, Inc. (TYME)

Stock Price: $1.33 USD -0.01 (-0.37%)
Updated Jun 17, 2021 2:07 PM EDT - Market open
Market Cap 229.04M
Revenue (ttm) n/a
Net Income (ttm) -28.98M
Shares Out 154.17M
EPS (ttm) -0.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 17
Last Price $1.33
Previous Close $1.34
Change ($) -0.01
Change (%) -0.37%
Day's Open 1.34
Day's Range 1.31 - 1.35
Day's Volume 819,707
52-Week Range 0.85 - 4.99

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Looking for biotech penny stocks to watch before Monday? Check these 3 out The post Best Biotech Penny Stocks to Buy?

Other stocks mentioned: AXLA, IBIO
6 days ago - PennyStocks

Tyme Technologies Inc (NASDAQ: TYME) announced a breast cancer trial with Georgetown University named OASIS. Enrollment is expected to start in Q3 of 2021.

6 days ago - Benzinga

BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (Nasdaq:TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today reporte...

6 days ago - Business Wire

Looking for biotech penny stocks on Reddit? Check these 3 out for your watchlist The post 3 Biotech Penny Stocks That Are Popular on Reddit Right Now appeared first on Penny Stocks to Buy, Picks, News a...

Other stocks mentioned: CRBP, EYES
2 weeks ago - PennyStocks

Biotech penny stocks are pushing up; here's 4 for your watchlist The post Top Biotech Penny Stocks to Watch in June 2021? Here's 4 For Your List appeared first on Penny Stocks to Buy, Picks, News and In...

Other stocks mentioned: ADXS, SESN, TTOO
2 weeks ago - PennyStocks

These penny stocks are pushing up, should you add them to your watchlist? The post Best Penny Stocks in 2021 So Far?

Other stocks mentioned: ABEO, LOTZ, OCG
3 weeks ago - PennyStocks

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “TYME”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTstm), today annou...

3 weeks ago - Business Wire

Looking for top penny stocks to buy under $2? Check these 3 out for some watchlist inspiration The post 3 Penny Stocks To Watch Under $2 Making Big Moves Today appeared first on Penny Stocks to Buy, Pic...

Other stocks mentioned: ADXS, NGD
4 weeks ago - PennyStocks

Express Inc (NYSE:EXPR) and Tyme Technologies Inc (NASDAQ:TYME) skyrocketed in January and February after gaining the attention of the WallStreetBets community. Now known as meme stocks, along with Game...

Other stocks mentioned: EXPR
4 weeks ago - Benzinga

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “Tyme”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announ...

1 month ago - Business Wire

BEDMINSTER, N.J.--(BUSINESS WIRE)--TYME Technologies, Inc. (Nasdaq: TYME) (the “Company” or “Tyme”), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announ...

1 month ago - Business Wire

BEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the appointment of Jan...

2 months ago - Business Wire

The company closed a $100 million public stock offering.

4 months ago - The Motley Fool

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that today it clos...

4 months ago - Business Wire

The clinical-stage biotech provides investors with a quarterly update.

4 months ago - The Motley Fool

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and oper...

4 months ago - Business Wire

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), today announced that it has...

4 months ago - Business Wire

The U.S. Patent and Trademark Office is on Tyme's side.

4 months ago - The Motley Fool

Tyme Technologies Inc (NASDAQ: TYME) shares are nearly doubling on above-average volume Wednesday. Tyme, which focuses on developing cancer metabolism-based therapies, said the U.S. Patent and Trademark...

4 months ago - Benzinga

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that it has receiv...

4 months ago - Business Wire

Revisiting Tyme Technologies

6 months ago - Seeking Alpha

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that an abstract h...

6 months ago - Business Wire

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced that, effective N...

6 months ago - Business Wire

In this article we are going to use hedge fund sentiment as a tool and determine whether Tyme Technologies, Inc. (NASDAQ:TYME) is a good investment right now. We like to analyze hedge fund sentiment bef...

6 months ago - Insider Monkey

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and oper...

7 months ago - Business Wire

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadershi...

8 months ago - Business Wire

TYME Technologies: My Bamboo Speculation In A Potential Leader In Cancer Metabolism-Based Therapies.

8 months ago - Seeking Alpha

Tyme has a solid product candidate in pancreatic cancer.

8 months ago - Seeking Alpha

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.

9 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership team wi...

9 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will p...

9 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will p...

9 months ago - Business Wire

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.

9 months ago - Business Wire

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.

9 months ago - Business Wire

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.

10 months ago - Business Wire

Tyme Technologies (NASDAQ: TYME) shares are trading higher on Monday after the company announced an orphan drug designation for its SM-88 as a potential treatment for patients with pancreatic cancer.

10 months ago - Benzinga

BEDMINSTER, N.J.--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc.

10 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will p...

10 months ago - Business Wire

Tyme Technologies Inc (NASDAQ:TYME) was trading 1.7% lower from the previous closing price.

11 months ago - Benzinga

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced preliminary financial and ...

11 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that TYME will hold its 20...

11 months ago - Business Wire

Tyme Technologies Inc (NASDAQ:TYME) was trading 0.2% lower from the previous closing price.

11 months ago - Benzinga

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced new preclinical findings t...

11 months ago - Business Wire

NEW YORK--(BUSINESS WIRE)---- $TYME--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced new preclinical findings t...

11 months ago - Business Wire

Tyme Technologies, Inc. (TYME) CEO Steve Hoffman on Q4 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Tyme Technologies: Market Volatility Provides Opportunity To Accumulate Ahead Of Catalysts

1 year ago - Seeking Alpha

Circling Back On Tyme Technologies

1 year ago - Seeking Alpha

NEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the first s...

1 year ago - GlobeNewsWire

Tyme Technologies: Why Investors Should Be Bullish On The Eagle Partnership

1 year ago - Seeking Alpha

About TYME

Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead candidate is the SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, lung, breast, prostate, sarcoma, and lymphoma. The company also offers TYME-19, an oral synthetically produced member of the bile acid family, which is in preclinical stage for the treatment of COVID-19 and disease variants; and TYME-18, a CMBT compound that is in preclinical stage for t... [Read more...]

Industry
Biotechnology
Founded
2011
Stock Exchange
NASDAQ
Ticker Symbol
TYME
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for TYME stock is "Buy." The 12-month stock price forecast is 9.50, which is an increase of 614.29% from the latest price.

Price Target
$9.50
(614.29% upside)
Analyst Consensus: Buy